1. Salloway S, Sperling R, Honig L, et al. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease who are apolipoprotein E e4 non-carriers (presented at the 16th congress of the European Federation of Neurological Societies, Stockholm, Sweden, September 11, 2012). European Journal of Neurology 2012: 19(Suppl. 1), 70.
2. Sperling R, Salloway S, Raskind M, et al. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease who are apolipoprotein E e4 carriers (presented at the 16th Congress of the European Federation of Neurological Societies, Stockholm. Sweden, September 11, 2012). European Journal of Neurology 2012: 19(Suppl. 1), 70.
3. Doody, RS. Results of Immune-Based Trials in Neurological Disorders. Presented at the 2012 Annual Meeting of the American Neurological Association, Boston, Massachusetts, October 8, 2012.
4. Yang L, Rieves D, Ganley C. Brain amyloid imaging—FDA approval of florbetapir F18 injection. N Engl J Med. 2012; 367:885–887
5. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012; 367:795–804.